No Data
Express News | Transcode Therapeutics Announces Nasdaq Extension to Regain Compliance
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Maintains Target Price $3
TransCode Therapeutics: Pioneering MicroRNA-Based Cancer Therapy With Promising Clinical Progress
Express News | Transcode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
TransCode Therapeutics Shares Are Trading Higher After the Company Announced It's Dosed Patients in the First Cohort of Its Phase 1A Dose-escalation Clinical Trial of TTX-MC138.
Express News | Transcode Therapeutics Inc - No Significant Safety or Dose Limiting Toxicities Reported
No Data
No Data